Publicacións en colaboración con investigadores/as de Weill Cornell Medical College in Qatar (10)

2024

  1. A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer

    Future Oncology

  2. Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study

    ESMO Open, Vol. 9, Núm. 9

2023

  1. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

    The Lancet, Vol. 402, Núm. 10411, pp. 1423-1433

2015

  1. Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies[ Breast Cancer Res Treat (2014), 148, 553-561, DOI 10.1007/s10549-014-3144-y]

    Breast Cancer Research and Treatment

  2. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

    Science Translational Medicine, Vol. 7, Núm. 283

2014

  1. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

    Breast Cancer Research and Treatment, Vol. 148, Núm. 3, pp. 553-561

  2. Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer

    Oncologist, Vol. 19, Núm. 4, pp. 318-327

2013

  1. Dasatinib plus capecitabine for advanced breast cancer: Safety and efficacy in phase I study CA180004

    Clinical Cancer Research, Vol. 19, Núm. 7, pp. 1884-1893

2011

  1. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study

    The Lancet, Vol. 377, Núm. 9769, pp. 914-923

2010

  1. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer

    Clinical Breast Cancer